Gilead Sciences, Inc. $GILD Shares Bought by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,340,048 shares of the biopharmaceutical company’s stock after purchasing an additional 21,548 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Gilead Sciences were worth $148,745,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $2,150,268,000. Invesco Ltd. lifted its stake in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Finally, Amundi boosted its holdings in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday. Daiwa Capital Markets lifted their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. HSBC boosted their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Scotiabank initiated coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective for the company. Finally, Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

Insider Activity

In other news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This trade represents a 1.73% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 141,757 shares of company stock worth $17,569,112. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

NASDAQ GILD opened at $135.93 on Friday. Gilead Sciences, Inc. has a 1 year low of $92.26 and a 1 year high of $136.30. The business’s fifty day moving average is $123.98 and its two-hundred day moving average is $118.62. The stock has a market capitalization of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.69 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.